Netherlands· NL-c4c0a6507265

Ogsiveo 100 mg filmomhulde tabletten

A nirogacestat product containing nirogacestatdihydrobromide, registered in Netherlands by Merck Europe B.V.. The same ATC class is registered in 9 of our 19 countries.

ATC L01XX81

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about nirogacestatdihydrobromideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Nirogacestat is registered in 9 of 19 countries.

Countries holding a registration under ATC L01XX81 (nirogacestat), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
7 of them publish a price we can compare per daily dose

Search nirogacestat products by name

Nirogacestat · ATC L01XX81

9 / 19 countries

Belgiumprice
Czechiaprice
Finlandprice
Icelandprice
Ireland
Netherlands
Spainprice
Switzerlandprice
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)

Active substance: NIROGACESTATDIHYDROBROMIDE
Manufacturer: Merck Europe B.V.
Country: Netherlands (NL)
ATC code: L01XX81
ATC class: Nirogacestat
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
EU/1/25/1932

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under L01XX81

Nirogacestat, as other registers publish it.

All nirogacestat products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/ff7fdb3c-285a-4ddb-b625-294c60e50bbd
GET /v1/drugs/ff7fdb3c-285a-4ddb-b625-294c60e50bbd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ogsiveo-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Nirogacestat",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133037",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "COPOLYMEER VAN MACROGOL (25,0)-POLY(VINYL ALCOHOL) (75,0) (E 1209)",
    "GLYCEROL MONOCAPRYLOCAPRAAT, TYPE I",
    "IJZEROXIDE GEEL (E 172)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYVINYLALCOHOL (E 1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)",
    "ZONNEGEEL FCF ALUMINIUMLAK (E 110)"
  ],
  "substances": [
    "NIROGACESTATDIHYDROBROMIDE"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/08/14",
  "procedure_number": "EMEA/H/C/006071",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/1932",
  "additional_monitoring": "Y"
}

API reference MCP server Plans

See everything about nirogacestat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console